Utilisation of the ESMO-MCBS in practice of HTA

C. Wild; N. Grössmann; P.V. Bonanno; A. Bucsics; J. Furst; K. Garuoliene; B. Godman; J. Gulbinovič; J. Jones; M. K. Pomorski; R. Emprechtinger

doi:10.1093/annonc/mdw297

Utilisation of the ESMO-MCBS in practice of HTA

C. Wild^*, N. Grössmann, P.V. Bonanno, A. Bucsics, J. Furst, K. Garuoliene, B. Godman, J. Gulbinovič, J. Jones, M. K. Pomorski, R. Emprechtinger

^*Corresponding author for this work

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

45 Citations (Scopus)

38 Downloads (Pure)

Abstract

It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.

Original language	English
Pages (from-to)	2134-2136
Number of pages	3
Journal	Annals of Oncology
Volume	27
Issue number	11
Early online date	8 Aug 2016
DOIs	https://doi.org/10.1093/annonc/mdw297
Publication status	Published - 30 Nov 2016

Keywords

oncology
cancer therapies
clinical practice
oncology medicines

Access to Document

10.1093/annonc/mdw297

Wild-AOO-2016-Utilisation-of-the-ESMO-MCBS-in-practiceAccepted author manuscript, 601 KB

Cite this

@article{f39a20857aec4ac288d2f0616eeae8d7,

title = "Utilisation of the ESMO-MCBS in practice of HTA",

abstract = "It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years. ",

keywords = "oncology, cancer therapies, clinical practice, oncology medicines",

author = "C. Wild and N. Gr{\"o}ssmann and P.V. Bonanno and A. Bucsics and J. Furst and K. Garuoliene and B. Godman and J. Gulbinovi{\v c} and J. Jones and Pomorski, {M. K.} and R. Emprechtinger",

year = "2016",

month = nov,

day = "30",

doi = "10.1093/annonc/mdw297",

language = "English",

volume = "27",

pages = "2134--2136",

journal = "Annals of Oncology",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Utilisation of the ESMO-MCBS in practice of HTA

AU - Wild, C.

AU - Grössmann, N.

AU - Bonanno, P.V.

AU - Bucsics, A.

AU - Furst, J.

AU - Garuoliene, K.

AU - Godman, B.

AU - Gulbinovič, J.

AU - Jones, J.

AU - Pomorski, M. K.

AU - Emprechtinger, R.

PY - 2016/11/30

Y1 - 2016/11/30

N2 - It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.

AB - It is highly appreciated that the European Society of Medical Oncology has developed a system to assess new oncologic compounds according to their value to patients. Consequently, offering decision-support to those who either want to use the new cancer therapies in clinical practice but cannot keep up-to-date with all therapy options or, alternatively, to those who have to decide whether or not to fund new oncology medicines or exclude from reimbursement due to their low value. This is particularly important with ever-rising prices for new oncology medicines which have increased up to ten fold in recent years.

KW - oncology

KW - cancer therapies

KW - clinical practice

KW - oncology medicines

UR - https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw297

U2 - 10.1093/annonc/mdw297

DO - 10.1093/annonc/mdw297

M3 - Article

C2 - 27502718

SN - 1569-8041

VL - 27

SP - 2134

EP - 2136

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Utilisation of the ESMO-MCBS in practice of HTA

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this